E3 ubiquitin ligase HECTD2 mediates melanoma progression and immune evasion

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• The ubiquitin-proteasome system is crucial for protein homeostasis and cell cycle regulation, with dysregulation observed in cancer.
• Individual E3 ubiquitin ligases, key regulators of proteolysis, have incompletely understood roles in cancer progression.
• HECTD2 is an understudied E3 ubiquitin ligase identified through cancer-specific retroviral transcript screening.

Purpose of the Study:

• To investigate the role of the E3 ubiquitin ligase HECTD2 in melanoma tumor progression.
• To elucidate HECTD2's mechanisms in regulating cancer cell proliferation and immune evasion.
• To assess the therapeutic potential of targeting HECTD2 in melanoma.

Main Methods:

• Screening for cancer-specific endogenous retroviral transcripts to identify novel genes.
• Functional assays in human and murine melanoma cell lines to assess HECTD2's impact on proliferation and cell cycle.
• Analysis of immune mediator production, including the cyclooxygenase 2 (COX2) pathway.
• Correlation of HECTD2 expression with anti-tumor immunity and response to PD-1 blockade in human melanoma.
• Evaluation of HECTD2's effect on anti-tumor immunity in a murine melanoma model.

Main Results:

• HECTD2 significantly drives tumor progression in melanoma.
• HECTD2 autonomously promotes melanoma cell proliferation by accelerating the cell cycle.
• HECTD2 regulates immune mediator production, activating immunosuppressive pathways like COX2.
• Higher HECTD2 expression correlates with reduced anti-tumor immunity and poor outcomes with PD-1 blockade therapy.
• HECTD2 counteracts anti-tumor immunity in a murine melanoma model.

Conclusions:

• HECTD2 plays a central, multifaceted role in melanoma, promoting both cancer cell-autonomous proliferation and immune evasion.
• Targeting HECTD2 presents a potential single-target strategy for a multipronged therapeutic approach in melanoma.